source
- Roche signs $1.2 bn obesity partnership with China's Rona Therapeutics, paying up to $100 m upfrontRoche announced its seventh China deal this year, partnering with RNA‑interference specialist Rona Therapeutics to target obesity. The collaboration licenses an ALK7 inhibition asset and includes…
- Verdiva Bio halts mid-stage obesity trial of its GLP-1 pill, citing market evolutionVerdiva Bio, a well-funded private biotech, announced it has terminated one of its Phase 2 trials for its lead oral GLP-1 obesity candidate. The company said the decision reflects a shift in the m…